Skip to main content

Advertisement

SpringerLink
Log in

Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndrome (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT should be performed is unclear. We analyzed BRT and the outcomes of patients with myelodysplastic syndrome with excess blasts (MDS-EB) who were ≤ 70 years old at the time of registration for a prospective observational study to clarify the optimal allo-SCT strategy for high-risk MDS. A total of 371 patients were included in this study. Among 188 patients (50.7%) who were considered for allo-SCT, 141 underwent allo-SCT. Among the patients who underwent allo-SCT, 64 received AZA, 29 received CCT, and 26 underwent allo-SCT without BRT as the initial treatment. Multivariate analysis identified BRT as an independent factor influencing overall survival (AZA vs. without BRT, hazard ratio [HR] 3.33, P = 0.005; CCT vs. without BRT, HR 3.82, P = 0.003). In multivariate analysis, BRT was independently associated with progression-free survival (AZA vs. without BRT: HR, 2.23; P = 0.041; CCT vs. without BRT: HR, 2.94; P = 0.010). Transplant-eligible patients with MDS-EB should undergo allo-SCT when clinically acceptable, and upfront allo-SCT without BRT may be superior to AZA or CCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on a collaborative basis.

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199

    Article  PubMed  CAS  Google Scholar 

  2. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes–coping with ineffective hematopoiesis. N Engl J Med 352(6):536–538. https://doi.org/10.1056/NEJMp048266

    Article  PubMed  CAS  Google Scholar 

  3. Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G (2015) HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia 29(7):1496–1501. https://doi.org/10.1038/leu.2015.37

    Article  PubMed  CAS  Google Scholar 

  4. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C (2021) Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol: Off J Am Soc Clin Oncol 39(30):3328–3339. https://doi.org/10.1200/jco.20.03380

    Article  CAS  Google Scholar 

  5. Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U (2021) Comparison between 5-Azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol: Off J Am Soc Clin Oncol 39(30):3318–3327. https://doi.org/10.1200/jco.20.02724

    Article  Google Scholar 

  6. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN, Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, Keating A, Weisdorf DJ, de Witte TM, Horowitz MM (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100(6):1997–2004

    PubMed  CAS  Google Scholar 

  7. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen JJ, Schouten HC, Carreras E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte TM (2002) Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99(12):4370–4378. https://doi.org/10.1182/blood.v99.12.4370

    Article  PubMed  CAS  Google Scholar 

  8. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL (2012) Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 18(8):1211–1218. https://doi.org/10.1016/j.bbmt.2012.01.009

    Article  CAS  Google Scholar 

  9. Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I (2012) Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol: Off J Am Soc Clin Oncol 30(36):4533–4540. https://doi.org/10.1200/jco.2012.44.3499

    Article  CAS  Google Scholar 

  10. Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S (2017) Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol: Off J Eur Soc Med Oncol 28(7):1547–1553. https://doi.org/10.1093/annonc/mdx154

    Article  CAS  Google Scholar 

  11. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler C (2013) Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol: Off J Am Soc Clin Oncol 31(21):2662–2670. https://doi.org/10.1200/jco.2012.46.8652

    Article  Google Scholar 

  12. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104(2):579–585. https://doi.org/10.1182/blood-2004-01-0338

    Article  PubMed  CAS  Google Scholar 

  13. Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A (2013) Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? J Clin Oncol: Off J Am Soc Clin Oncol 31(21):2761–2762. https://doi.org/10.1200/jco.2012.48.0525

    Article  Google Scholar 

  14. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol: Off J Am Soc Clin Oncol 30(8):820–829. https://doi.org/10.1200/jco.2011.35.6394

    Article  Google Scholar 

  15. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. https://doi.org/10.1182/blood-2012-03-420489

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

    Article  PubMed  CAS  Google Scholar 

  17. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ (2005) Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 11(1):65–73. https://doi.org/10.1016/j.bbmt.2004.10.001

    Article  Google Scholar 

  18. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S (2005) Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19(3):396–401. https://doi.org/10.1038/sj.leu.2403640

    Article  PubMed  CAS  Google Scholar 

  19. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE (2014) Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 20(10):1618–1625. https://doi.org/10.1016/j.bbmt.2014.06.022

    Article  CAS  Google Scholar 

  20. Onida F, Brand R, van Biezen A, Schaap M, von dem Borne PA, Maertens J, Beelen DW, Carreras E, Alessandrino EP, Volin L, Kuball JH, Figuera A, Sierra J, Finke J, Kröger N, de Witte T (2014) Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica 99(10):1582–1590. https://doi.org/10.3324/haematol.2014.106880

    Article  PubMed  PubMed Central  Google Scholar 

  21. Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K (2019) Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol 37(1):85–95. https://doi.org/10.1002/hon.2566

    Article  PubMed  CAS  Google Scholar 

  22. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382):506–510. https://doi.org/10.1038/nature10738

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, Li C, Shedden K, Malek SN (2013) Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 121(2):369–377. https://doi.org/10.1182/blood-2012-04-427039

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Ann Hematol 94(1):23–34. https://doi.org/10.1007/s00277-014-2177-y

    Article  PubMed  Google Scholar 

  25. Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, Kondakci M, Haas R, Germing U, Kobbe G (2019) Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 25(8):1550–1559. https://doi.org/10.1016/j.bbmt.2019.03.011

    Article  Google Scholar 

  26. Rautenberg C, Germing U, Stepanow S, Lauseker M, Köhrer K, Jäger PS, Geyh S, Fan M, Haas R, Kobbe G, Schroeder T (2021) Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia. Am J Hematol 96(1):E15-e17. https://doi.org/10.1002/ajh.26013

    Article  PubMed  CAS  Google Scholar 

  27. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL (2017) Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 376(6):536–547. https://doi.org/10.1056/NEJMoa1611604

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M (2016) Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol: Off J Am Soc Clin Oncol 34(30):3627–3637. https://doi.org/10.1200/jco.2016.67.3616

    Article  Google Scholar 

  29. Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H, Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H, Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA, Maciejewski JP, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129(17):2347–2358. https://doi.org/10.1182/blood-2016-12-754796

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We appreciate all physicians and staff participating in the JALSG-CS11-MDS-SCT study. We are grateful to the JALSG staff.

Funding

Funded by Japan Adult Leukemia Study Group (JALSG).

Author information

Author notes

  1. Noriharu Nakagawa and Ken Ishiyama contributed equally to this work.

Authors and Affiliations

  1. Department of Internal Medicine, Keiju Medical Center, Nanao, Japan

    Noriharu Nakagawa

  2. Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan

    Noriharu Nakagawa, Ken Ishiyama & Shigeki Ohtake

  3. Department of Hematology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku, Tokyo, 162-8655, Japan

    Ken Ishiyama

  4. Department of Hematology, NTT Medical Center Tokyo, Shinagawa, Japan

    Kensuke Usuki

  5. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

    Satoru Takada

  6. Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

    Tatsuki Tomikawa

  7. Department of Hematology, Gunma University Hospital, Maebashi, Japan

    Hiroshi Handa

  8. Department of Hematology, Sendai Medical Center, National Hospital Organization, Sendai, Japan

    Yuna Katsuoka

  9. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    Daiki Hirano

  10. Department of Hematology, Chugoku Central Hospital, Miyukichokamiiwanari, Japan

    Nobuo Sezaki

  11. Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan

    Masahiko Sumi

  12. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    Shin Fujisawa

  13. Department of Hematology and Rheumatology, Kindai University Hospital, Osakasayama, Japan

    Yasuhiro Taniguchi & Itaru Matsumura

  14. Department of Hematology, Fuchu Hospital, Izumi, Japan

    Atsuko Mugitani

  15. Department of Hematology, Osaka City General Hospital, Osaka, Japan

    Takuro Yoshimura

  16. Department of Hematology, Oita Prefectural Hospital, Oita, Japan

    Eiichi Ohtsuka

  17. Department of Hematology, Kyushu Medical Center, Fukuoka, Japan

    Ken Takase

  18. Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Youko Suehiro

  19. Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan

    Shuichi Ota

  20. Department of Hematology and Oncology, Tosei General Hospital, Seto, Japan

    Tomohiro Kajiguchi

  21. Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Hidaka, Japan

    Tomoya Maeda

  22. Department of Hematology, Tokyo Medical and Dental University, Bunkyo, Japan

    Masahide Yamamoto

  23. Department of Hematology, National Center for Geriatrics and Gerontology, Obu, Japan

    Akira Katsumi

  24. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Hitoshi Kiyoi

  25. Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan

    Yasushi Miyazaki

Authors
  1. Noriharu Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kensuke Usuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoru Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatsuki Tomikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Handa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuna Katsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daiki Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobuo Sezaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiko Sumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shin Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yasuhiro Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Atsuko Mugitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takuro Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Eiichi Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ken Takase
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Youko Suehiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Shuichi Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tomohiro Kajiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Tomoya Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Masahide Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Shigeki Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Akira Katsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Hitoshi Kiyoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Itaru Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Yasushi Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, and Yasushi Miyazaki designed the study. Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda and Masahide Yamamoto collected clinical data. Noriharu Nakagawa and Ken Ishiyama analyzed the data and wrote the manuscript. All the authors critically reviewed the manuscript and checked the final version.

Corresponding author

Correspondence to Ken Ishiyama.

Ethics declarations

Ethical approval

This study was approved as an accompanying study of JALSG-CS-11 by the committee for the Japan Adult Leukemia Study Group (JALSG) and by the ethical committee of Kanazawa University (No. 2018–227) and all participating institutions. Informed consent was obtained from all the participants.

Conflict of interest

Kensuke Usuki has received research funding from Astellas-Amgen-Biopharma, Otsuka, Apellis, SymBio, Takeda, Nippon Shinyaku, Novartis, AbbVie, Janssen, Bristol-Myers Squibb, Ono, Chugai, Daiichi Sankyo, MSD, Astellas, Alexion, Kyowa-Kirin, Gilead, Pfizer, Incyte, SymBio, Celgene, Sumitomo-Dainippon, Mundi, Yakult, and Eisai, and has served on speaker bureaus for Novartis, Astellas, Alexion, Eisai, MSD, Otsuka, Ono, Kyowa-Kirin, Celgene, Daiichi Sankyo, Takeda, Nippon-Shinyaku, PharmaEssentia, Bristol-Myers Squibb, Yakult, Sanofi, Pfizer, AbbVie, and Chugai, and has served on consulting bureaus for Alexion, SymBio, Nippon Shinyaku, Otsuka, Chugai, Sanofi, Takeda, Kyowa-Kirin, Astellas, SOBI, and Alnylam Japan. Shin Fujisawa received honoraria from Bristol-Myers-Squibb, Astellas, Nippon Shinyaku, Otsuka, Pfizer, Novartis, MSD, Sanofi, Janssen, SymBio, Kyowa Hakko Kirin, AstraZeneca, CSL Behring, Meiji Seika Pharma, AbbVie, Takeda, and Chugai, and received research funding from Shionogi, Kyowa Hakko Kirin, Chugai, Otsuka, Asahi-Kasei, and Daiichi Sankyo. Tomoya Maeda received honoraria from Amgen, Nippon Becton Dickinson Company, Nippon Shinyaku, Novartis, Otsuka, Pfizer, and TOPPAN and received research funding from Chugai, Eisai, and Sumitomo Pharma. Masahide Yamamoto received honoraria from Bristol-Myers Squibb, Chugai, Eisai, Kyowa-Kirin, Nippon Shinyaku, Novartis, Ono, Otsuka, Pfizer, Takeda, Sanofi, Janssen, AbbVie, SymBio, and Meiji Seika. Hitoshi Kiyoi received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, AbbVie, CURED, Astellas, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, Sanofi, and Honoraria from AbbVie, Chugai, Astellas Pharma, and Novartis. Itaru Matsumura has received research funding from Kyowa-Kirin, Chugai, Novartis, Astellas, AbbVie, Pfizer, Takeda, Alexion, Otsuka, Janssen, Sumitomo-Dainippon, Shionogi, Asahi-Kasei, Eisai, TAIHO, Nippon Shinyaku, Ono, Sanofi, and Mitsubashi Tanabe and has received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Otsuka, Astellas, Janssen, AbbVie, Takeda, Ono, and SymBio. Yasushi Miyazaki received honoraria from Nippon Shinyaku, Bristol-Myers Squib, Novartis, Sumitomo Pharma, Kyowa-Kirin, AbbVie, Daiichi-Sankyo, Takeda, Janssen Pharmaceutical, Astellas, Pfizer, Chugai, SymBio, and Otsuka Pharmaceutical, and research funding from Sumitomo-Dainippon.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplemental figure 1.

The survival of patients in the SCT-considered cohort with blasts ≥10% at the diagnosis. A. The overall survival of patients treated with each BRT. B. The overall survival of patients with each BRT adjusted for background factors, including age, sex, PS at diagnosis, cytogenetic risk, and allo-SCT (PNG 143 kb)

High resolution image (TIF 577 kb)

Supplemental figure 2.

The survival of patients in the transplant cohort. A. The overall survival according to sex. B: The overall survival according to cytogenetic risk. C. The overall survival according to sex and cytogenetic risk (PNG 209 kb)

High resolution image (TIF 664 kb)

Supplementary file3 (XLSX 12 KB)

Supplementary file4 (XLSX 11 KB)

Supplementary file5 (XLSX 11 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakagawa, N., Ishiyama, K., Usuki, K. et al. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT. Ann Hematol 103, 307–320 (2024). https://doi.org/10.1007/s00277-023-05527-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05527-5

Keywords

Search

Navigation